Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial
Open accessThe DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
Background: The effects of the sodium-glucose co-transporter 2 inhibitor empagliflozin on renal and cardiovascular disease have not been tested in a dedicated population of people with chronic kidney disease (CKD). Methods: The EMPA-KIDNEY trial is an international randomized, double-blind, placebo-controlled trial assessing whether empagliflozin 10 mg daily decreases the risk of kidney disease progression or cardiovascular death in people with CKD. People with or without diabetes mellitus (DM) were eligible provided they had an estimated glomerular filtration rate (eGFR) ≥20 but <45 mL/min/1.73 m2 or an eGFR ≥45 but <90 mL/min/1.73 m2 with a urinary albumin:creatinine ratio (uACR) ≥200 mg/g. The trial design is streamlined, as extra work for collaborating sites is kept to a minimum and only essential information is collected. Results: Between 15 May 2019 and 16 April 2021, 6609 people from eight countries in Europe, North America and East Asia were randomized. The mean age at randomization was 63.8 years [standard deviation (SD) 13.9)], 2192 (33%) were female and 3570 (54%) had no prior history of DM. The mean eGFR was 37.5 mL/min/1.73 m2 (SD 14.8), including 5185 (78%) with an eGFR <45 mL/min/1.73 m2. The median uACR was 412 mg/g) (quartile 1–quartile 3 94–1190), with a uACR <300 mg/g in 3194 (48%). The causes of kidney disease included diabetic kidney disease [n = 2057 (31%)], glomerular disease [n = 1669 (25%)], hypertensive/renovascular disease [n = 1445 (22%)], other [n = 808 (12%)] and unknown causes [n = 630 (10%)]. Conclusions: EMPA-KIDNEY will evaluate the efficacy and safety of empagliflozin in a widely generalizable population of people with CKD at risk of kidney disease progression. Results are anticipated in 2022.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Since 2021, two placebo-controlled SGLT2 inhibitor trials (EMPA-KIDNEY and DELIVER) have studied a large number of people without diabetes.”
From Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials (2022) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“EMPA-KIDNEY recruited 6609 patients with chronic kidney disease including 3569 patients without diabetes”
From Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials (2022) · cites this paper as [12]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Follow-up was planned until at least 1070 participants had experienced a first primary outcome, in order to provide 90% power at two-sided P=0.05 to detect an 18% relative reduction in risk.14”
From Empagliflozin in Patients with Chronic Kidney Disease (2023) · cites this paper as [14]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Toprak, O., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,627
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603 · cited 1×
“All trial eGFR values are estimated using the Chronic Kidney Disease Epidemiology Collaboration creatinine formula available at the start of recruitment (i.e. adjustment for race was included) [39].”
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Self-citationAhmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization
Go, A. S., Chertow, G. M., Fan, D., McCulloch, C. E., & Hsu, C.-Y. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041031 · Cited by 11,369
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382 · cited 1×
“Since then, several other large placebo-controlled cardiovascular outcome trials with other SGLT-2 inhibitors have reported analogous findings [14, 16, 17].”
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189 · cited 9×
“A total of 6708 participants attended a randomization visit, of which 6609 were randomized (Supplementary data, Table S3b and Figure 3). characteristics of the CREDENCE and DAPA-CKD trials [18, 23–25].”
InfluentialSelf-citation
Research works printed but not linked: 1
- United States Renal Data System 2014 Annual Data Report: Atlas of End-stage Renal Disease in the United States 2014 Bethesda, MD National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases
Cited by
KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease
Stevens, P. E., Ahmed, S. B., Carrero, J. J., Foster, B., Francis, A., Hall, R. K., Herrington, W. G., Hill, G., Inker, L. A., Kazancıoğlu, R., et al. (2024) · Kidney International · doi:10.1016/j.kint.2023.10.018 · Cited by 8,530
Self-citationEmpagliflozin in Patients with Chronic Kidney Disease
The EMPA-KIDNEY Collaborative Group (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2204233 · Cited by 2,754
“14 The Protocol specified that a single formal interim analysis for efficacy should be conducted when 150 participants had experienced a first ESKD event.”
Self-citationBaigent, C., Emberson, J., Haynes, R., Herrington, W. G., Judge, P., Landray, M. J., Mayne, K. J., Ng, S. Y. A., Preiss, D., Roddick, A. J., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)02074-8 · Cited by 1,020
Self-citationMolecular mechanisms and therapeutic targets for diabetic kidney disease
Tuttle, K. R., Agarwal, R., Alpers, C. E., Bakris, G. L., Brosius, F. C., Kolkhof, P., & Uribarri, J. (2022) · Kidney International · doi:10.1016/j.kint.2022.05.012 · Cited by 668
Self-citationRossing, P., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2022) · Kidney International · doi:10.1016/j.kint.2022.06.013 · Cited by 274
Self-citationHeerspink, H. J. L., Radhakrishnan, J., Alpers, C. E., Barratt, J., Bieler, S., Diva, U., Inrig, J., Komers, R., Mercer, A., Noronha, I. L., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00569-x · Cited by 224
Yau, K., Dharia, A., Alrowiyti, I., & Cherney, D. Z. I. (2022) · Kidney International Reports · doi:10.1016/j.ekir.2022.04.094 · Cited by 223
“Kidney International Reports (2022) 7, 1463–1476 patients with glomerular disease (n 1⁄4 1669) and hypertensive/renovascular disease (n 1⁄4 1444).(58) The primary outcome of this trial was a sustained $40% decline in eGFR, ESKD, or death from renal or cardiovascular causes.”
Self-citationLong-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease
The EMPA-KIDNEY Collaborative Group (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2409183 · Cited by 156
Self-citationJudge, P., Staplin, N., Mayne, K., Wanner, C., Green, J., Hauske, S. J., Emberson, J., Preiss, D., Ng, S., Roddick, A., et al. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00322-4 · Cited by 155
“2,6,8 It also provides the largest amount of randomised data on the use of SGLT2 inhibition currently available for patients with chronic kidney disease at risk of progression.”
Self-citationEMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors
Fernández‐Fernández, B., Sarafidis, P. A., Soler, M. J., & Ortíz, A. (2023) · Clinical Kidney Journal · doi:10.1093/ckj/sfad082 · Cited by 146
Staplin, N., Haynes, R., Judge, P., Wanner, C., Green, J., Emberson, J., Preiss, D., Mayne, K., Ng, S., Sammons, E. L., et al. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00321-2 · Cited by 135
Self-citationHeerspink, H. J. L., Agarwal, R., Bakris, G. L., Cherney, D. Z. I., Lam, C. S. P., Neuen, B. L., Sarafidis, P. A., Tuttle, K. R., Wanner, C., BRINKER, M. D., et al. (2024) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfae132 · Cited by 110
“[37 , 38 ].”
InfluentialSelf-citationHow to Manage Heart Failure With Preserved Ejection Fraction
Desai, A. S., Lam, C. S. P., McMurray, J. J. V., & Redfield, M. M. (2023) · JACC Heart Failure · doi:10.1016/j.jchf.2023.03.011 · Cited by 96
IgA nephropathy in adults—treatment standard
Gleeson, P. J., O'Shaughnessy, M. M., & Barratt, J. (2023) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfad146 · Cited by 90
“In EMPA-Kidney, half of the non-diabetic patients with glomerular disease had IgAN, making up 12% of the overall study population, and effect-modification by cause of kidney disease was not observed [28 ].”
Mark, P. B., Sarafidis, P. A., Ekart, R., Ferro, C. J., Balafa, O. C., Fernández‐Fernández, B., Herrington, W. G., Rossignol, P., Vecchio, L. D., Valdivielso, J. M., et al. (2023) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfad112 · Cited by 87
“%) had IgAN, plus 68 patients with type 1 diabetes [ 57 ].”
Self-citationMancini, G. B. J., O’Meara, E., Zieroth, S., Bernier, M., Cheng, A. Y. Y., Cherney, D. Z. I., Connelly, K. A., Ezekowitz, J., Goldenberg, R. M., Leiter, L. A., et al. (2022) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2022.04.029 · Cited by 56
Self-citationSGLT2 Inhibitors: The Sweet Success for Kidneys
Dharia, A., Khan, A. A., Sridhar, V. S., & Cherney, D. Z. I. (2023) · Annual Review of Medicine · doi:10.1146/annurev-med-042921-102135 · Cited by 69
Self-citationMayne, K. J., Shemilt, R., Keane, D. F., Lees, J. S., Mark, P. B., & Herrington, W. G. (2022) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2022.08.005 · Cited by 66
Self-citationEffects of Empagliflozin on Fluid Overload, Weight, and Blood Pressure in CKD
Mayne, K. J., Staplin, N., Keane, D. F., Wanner, C., Brenner, S., Cejka, V., Stegbauer, J., Judge, P. K., Preiss, D., Emberson, J., et al. (2023) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000000000271 · Cited by 66
“11,16 In brief, patients with CKD at risk of progression were identi fi ed based on historical and screening local laboratory measurements of an eGFR $ 20 but , 45 ml/min per 1.73 m 2 , or an eGFR $ 45 but , 90 ml/min per 1.73 m 2 with a urinary albumin-creatinine ratio (uACR) $ 200 mg/g.”
InfluentialSelf-citationSGLT2 Inhibitors in Chronic Kidney Disease: From Mechanisms to Clinical Practice
Škrabić, R., Kumrić, M., Vrdoljak, J., Rušić, D., Skrabic, I., Vilović, M., Martinović, D., Duplancic, V., Kurir, T. T., & Božić, J. (2022) · Biomedicines · doi:10.3390/biomedicines10102458 · Cited by 59
Hyperkalemia: Prevalence, Predictors and Emerging Treatments
Larivée, N., Michaud, J. B., More, K. M., Wilson, J.-A. S., & Tennankore, K. (2022) · Cardiology and Therapy · doi:10.1007/s40119-022-00289-z · Cited by 60
“73 m(2)) [81, 82] or heart failure, especially when otherwise clinically indicated.”
BackgroundDrugs in Clinical Development to Treat Autosomal Dominant Polycystic Kidney Disease
Bais, T., Gansevoort, R. T., & Meijer, E. (2022) · Drugs · doi:10.1007/s40265-022-01745-9 · Cited by 43
Mentz, R. J., Brunton, S., & Rangaswami, J. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-02023-y · Cited by 41
Agarwal, R., Green, J. B., Heerspink, H. J. L., Mann, J. F. E., McGill, J. B., Mottl, A. K., Rosenstock, J., Rossing, P. R., Vaduganathan, M., BRINKER, M. D., et al. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf022 · Cited by 38
Self-citationMayne, K. J., Sardell, R. J., Staplin, N., Judge, P. K., Zhu, D., Sammons, E. L., Cherney, D. Z. I., Cheung, A. K., Maggioni, A. P., Nangaku, M., et al. (2024) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000000000498 · Cited by 37
“Per 1000 participants treated, it was estimated that occurrences of kidney disease progression or cardiovascular death ( i.e ., primary outcomes) were avoided by empagli fl ozin in 35, 25, and 14 participants per year in the top, middle, and lowest thirds of frailty, respectively.”
Self-citationIgA Nephropathy Patient Baseline Characteristics in the Sparsentan PROTECT Study
Barratt, J., Rovin, B. H., Wong, M. G., Alpers, C. E., Bieler, S., He, P., Inrig, J. K., Komers, R., Heerspink, H. J. L., Mercer, A., et al. (2023) · Kidney International Reports · doi:10.1016/j.ekir.2023.02.1086 · Cited by 33
Nephroprotective Properties of Antidiabetic Drugs
Gerdes, C., Muller, N., Wolf, G., & Busch, M. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12103377 · Cited by 31
“The mean UACR was only 412 (94–1190) mg/g [74].”
Yau, K., Dharia, A., Alrowiyti, I., & Cherney, D. Z. I. (2022) · Kidney International Reports · doi:10.1016/j.ekir.2022.08.016 · Cited by 30
“This trial will therefore provide crucial data regarding patients with stage 4 CKD.(10) Finally, we agree that there is a paucity of data regarding the effect of combination therapy with SGLT2 inhibitors and GLP-1-RA in patients with CKD.”
Self-citationEffects of Dapagliflozin on Hospitalizations in Patients With Chronic Kidney Disease
Schechter, M., Jongs, N., Chertow, G. M., Mosenzon, O., McMurray, J. J. V., Correa‐Rotter, R., Rossing, P. R., Langkilde, A. M., Sjöström, C. D., Toto, R. D., et al. (2022) · Annals of Internal Medicine · doi:10.7326/m22-2115 · Cited by 29
Cardiorenal Syndromes and Their Role in Water and Sodium Homeostasis
Salajová, K. B., Malík, J., & Valeriánová, A. (2024) · Physiological Research · doi:10.33549/physiolres.935110 · Cited by 29
Novel Markers in Diabetic Kidney Disease—Current State and Perspectives
Piwkowska, A., Zdrojewski, Ł., Heleniak, Z., & Dębska-Ślizień, A. M. (2022) · Diagnostics · doi:10.3390/diagnostics12051205 · Cited by 27
Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors and CKD: Are You a #Flozinator?
Krishnan, A., Shankar, M., Lerma, E. V., & Wiegley, N. (2023) · Kidney Medicine · doi:10.1016/j.xkme.2023.100608 · Cited by 28
Application of SGLT-2 inhibitors in non-diabetic CKD: mechanisms, efficacy, and safety
Zhang, B., & Deng, L. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1574693 · Cited by 24
“The participants include patients with various types of CKD, both diabetic and non-diabetic (81).”
Kowalska, K., Wilczopolski, P., Buławska, D., Młynarska, E., Rysz, J., & Franczyk, B. (2022) · Antioxidants · doi:10.3390/antiox11122500 · Cited by 23
“However, numerous studies such as EMPA-KIDNEY and EMPULSE are being conducted to investigate the pleiotropic properties of flozins; therefore, the potential of this drug class has not yet been exploited [39].”
IgA nephropathy: an overview of drug treatments in clinical trials
Selvaskandan, H., Gonzalez-Martin, G., Barratt, J., & Cheung, C. K. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2160315 · Cited by 22
“Of note, those who could not tolerate RAS inhibition were also included [163] Like DAPA-CKD, EMPAKIDNEY was also terminated early due to treatment efficacy at preventing the primary composite outcome (40% decline in eGFR, sustained decrease in eGFR to < 10 ml/min/1.”
Pistelli, L., Parisi, F., Correale, M., Cocuzza, F., Campanella, F., Ferrari, T. D., Crea, P., Sarro, R. D., Cognata, O. M. L., Ceratti, S., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12010379 · Cited by 22
Cherney, D. Z. I., Bell, A., Girard, L., McFarlane, P. A., MOIST, L. M., Nessim, S. J., Soroka, S. D., Stafford, S. G., Steele, A., Tangri, N., et al. (2023) · Canadian Journal of Kidney Health and Disease · doi:10.1177/20543581221150556 · Cited by 22
Self-citationMa, C., Li, X., Li, W., Li, Y., Shui, F., & Zhu, P. (2023) · International Urology and Nephrology · doi:10.1007/s11255-023-03586-1 · Cited by 22
“The EMPA-KIDNEY trial [17] enrolled 6.609 patients with chronic kidney disease who had an estimated glomerular filtration rate (eGFR) of at least 20 but less than 90 ml/min/1.73 m 2 with a urinary albumin-to-creatinine ratio of at least 200 mg/g.”
InfluentialDapagliflozin for the treatment of chronic kidney disease
Kurata, Y., & Nangaku, M. (2022) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2022.2099373 · Cited by 21
Self-citationUpdate on diabetic kidney disease
Rico-Fontalvo, J. E., Jiménez, L. C. V., Yánez, T. R., Daza-Arnedo, R., Raad-Sarabia, M., Hernández, J. D. M., Vargas, M. L., & Quintero, J. J. (2022) · Anales de la Facultad de Ciencias Médicas (Asunción) · doi:10.18004/anales/2022.055.03.86 · Cited by 21
Sparsentan: A First-in-Class Dual Endothelin and Angiotensin II Receptor Antagonist
Chiu, A. W., & Bredenkamp, N. (2023) · Annals of Pharmacotherapy · doi:10.1177/10600280231198925 · Cited by 19
“35,36 Patients in the double-blind phase of PROTECT were not permitted to be on SGLT2 inhibitors, however, the open-label extension period will allow for this and may inform on the potential benefit of combination DEARA and SGLT2 inhibitor therapy.”
Shaikh, A., Ray, J., & Campbell, K. N. (2022) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s325916 · Cited by 18
“73m(2) and those with normal, or mildly increased albuminuria.(58) This trial was stopped early due to clear positive efficacy based on interim analysis, with pending published results expected to broaden our understanding of the role of SGLT2i across the full spectrum of eGFR and albuminuria.”
Neumiller, J. J., Lienhard, F. J., Alicic, R. Z., & Tuttle, K. R. (2022) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2022.18.2.106 · Cited by 18
Self-citationModern Approaches for the Treatment of Heart Failure: Recent Advances and Future Perspectives
Popa, I. P., Haba, M. Ș. C., Maranducă, M. A., Tănase, D. M., Șerban, D. N., Șerban, L., Iliescu, R., & Tudorancea, I. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091964 · Cited by 17
SGLT2 Inhibition in Heart Failure with Preserved Ejection Fraction — The New Frontier
Aguiar‐Neves, I., Santos‐Ferreira, D., & Fontes‐Carvalho, R. (2023) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2401001 · Cited by 16
“…proteinuria: one group including patients with an eGFR between 20 and 45 mL/min/1.73 m 2 (CKD-EPI formula); and the other including patients with an eGFR between 45 and 90 mL/min/1.73 m 2 as well as a urinary albumin-to-creatinine ratio ≥ 200 mg/g (or protein:creatinine ratio ≥ 300 mg/g) [ 62].”
InfluentialBak, M., Ah, S., Jeon, K., Hong, D., Shin, H.-Y., Kim, D., & Choi, J. (2024) · Scientific Reports · doi:10.1038/s41598-024-71231-7 · Cited by 16
Therapeutic approaches and novel antifibrotic agents in renal fibrosis: A comprehensive review
Lahane, G. P., Dhar, A., & Bhat, A. (2024) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.23795 · Cited by 14
Effects of Empagliflozin on Urine Biomarkers in EMPA-KIDNEY
Malijan, G. M., Sardell, R. J., Staplin, N., Devuyst, O., Chapman, D., Hill, M., Nägele, N., Moffat, S., Wijayaratne, D. R., Donovan, K., et al. (2025) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2025.10.004 · Cited by 14
Self-citation[EMPA-KIDNEY: empagliflozin in chronic kidney disease].
Delanaye, P., & Scheen, A. J. (2023) · PubMed · Cited by 14
Jarraya, F., Niang, A., Bagha, H., Tannor, E. K., Sumaili, E. K., Wan, D. I. M., Chothia, M., Mengistu, Y. T., Kaze, F. F., Ulasi, I., et al. (2023) · Kidney International Reports · doi:10.1016/j.ekir.2023.12.019 · Cited by 15
“61,83,84 Unlike the DAPA-CKD trial, the EMPA-KIDNEY encompassed a larger representation of patients within the G2A2 CKD subgroup, thereby extending the SGLT2i intervention to patients with lower risk and higher eGFR.”
InfluentialZhou, J., Williams, C., Staplin, N., Judge, P. K., Mayne, K. J., Agrawal, N., Arimoto, R., Green, J. B., Cherney, D. Z. I., Tuttle, K. R., et al. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103338 · Cited by 13
“14 The relevant regulatory authorities and research ethics committees/ institutional review boards representing each centre approved the trial and its post-trial follow-up.”
Self-citationNashar, K., & Khalil, P. (2022) · International Journal of Nephrology and Renovascular Disease · doi:10.2147/ijnrd.s234282 · Cited by 14
“The results are not published at the time of writing this manuscript.(41) The choice of SGLT-2 inhibitor should be based upon the current FDA indication, the patient’s kidney function at time of initiation as well as affordability.”
Berezina, T. A., Fushtey, I. M., Berezin, A. A., Pavlov, S. V., & Berezin, A. Е. (2023) · Advances in Therapy · doi:10.1007/s12325-023-02683-y · Cited by 13
Mark, P. B., & Sattar, N. A. (2022) · The Lancet · doi:10.1016/s0140-6736(22)02164-x · Cited by 12
Elkeraie, A. F., Zyada, R. S., Elrggal, M. E., & Elrggal, M. E. (2023) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-023-03508-1 · Cited by 12
Mathur, V. S., Bushinsky, D. A., Inker, L. A., Klaerner, G., Li, E., Parsell, D. A., Perkovic, V., Stasiv, Y., Walker, M. A., Wesson, D. E., et al. (2022) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfac289 · Cited by 11
Wang, W., Ke, B., Wang, C., Xiong, X., Feng, X., & Yan, H. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1607701 · Cited by 10
“However, cross-scale models (e.g., PhysiCell) are required to quantify synergy and toxicity risks (148, 149).”
Incorporating Evidence and Guidelines for Personalized Care of Diabetes and Chronic Kidney Disease
Neumiller, J. J., Alicic, R. Z., & Tuttle, K. R. (2023) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2023.151427 · Cited by 10
Self-citationHadjadj, S., Cooper, M. E., Steubl, D., Petrini, M., Hantel, S., Mattheus, M., Wanner, C., & Thomas, M. C. (2023) · Kidney Medicine · doi:10.1016/j.xkme.2023.100783 · Cited by 10
Self-citationNangaku, M., Herrington, W. G., Goto, S., Maruyama, S., Kashihara, N., Ueki, K., Wada, J., Watada, H., Nakashima, E., Lee, R., et al. (2024) · Clinical and Experimental Nephrology · doi:10.1007/s10157-024-02489-4 · Cited by 10
“Details of EMPA–KIDNEY’s rationale [7], design [8], protocol, pre-specified data analysis plan, and main results have been reported previously [6].”
Self-citationClinical trial designs of emerging therapies for diabetic kidney disease (DKD)
Singh, A. K., Farag, Y. M. K., Zheng, Z., & Bakris, G. L. (2024) · Postgraduate Medicine · doi:10.1080/00325481.2024.2377529 · Cited by 10
Rossing, P. R., Caramori, M. L., Chan, J. C. N., & Al., E. (2023) · KIDNEYS · doi:10.22141/2307-1257.11.4.2022.386 · Cited by 10
Mochel, J. P., Ward, J. L., Blondel, T., Kundu, D., Merodio, M. M., Zemirline, C., Guillot, E., Giebelhaus, R. T., de la Mata, A. P., Iennarella‐Servantez, C. A., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-71202-y · Cited by 11
Bramlage, P., Lanzinger, S., Mühldorfer, S., Milek, K., Gillessen, A., Veith, R., Ohde, T., Danne, T., Holl, R. W., & Seufert, J. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01840-5 · Cited by 9
Nielsen, S. F., Duus, C. L., Buus, N. H., Bech, J. N., & Mose, F. H. (2024) · JMIR Research Protocols · doi:10.2196/56067 · Cited by 9
Anuforo, A. C., Soipe, A. I., Awoyemi, T., Hanif, M., Adeniran, O. F., Somerville, A., Nnekachi, N. P., Chilaka, F., Aronow, W. S., & Yandrapalli, S. (2024) · International Journal of Cardiology · doi:10.1016/j.ijcard.2024.132914 · Cited by 9
Ambery, P., Greasley, P. J., Menzies, R. I., Brynne, L., Kulkarni, S., Oscarsson, J., & Davenport, A. P. (2024) · Clinical Science · doi:10.1042/cs20240605 · Cited by 8
State-of-Art Therapeutics in IgA Nephropathy
Mathur, M., Sahay, M., Pereira, B. J. G., & Rizk, D. V. (2024) · Indian Journal of Nephrology · doi:10.25259/ijn_319_23 · Cited by 8
Zhu, D., Judge, P. K., Staplin, N., Haynes, R., & Herrington, W. G. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfae210 · Cited by 7
“From these types of data, patients with CKD who fit the eligibility criteria for a trial can be identified and pre-invited by local research centres at scale [39 ].”
Self-citationWright, W. L., Urquhart, S., & Brunton, S. (2023) · Journal of Primary Care & Community Health · doi:10.1177/21501319231153599 · Cited by 7
Effects of Dapagliflozin in People without Diabetes and with Microalbuminuria
Heerspink, H. J. L., Chertow, G. M., Jongs, N., Correa‐Rotter, R., Rossing, P. R., Sjöström, C. D., Langkilde, A. M., & Wheeler, D. C. (2022) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.07290622 · Cited by 7
Rastogi, A., Collins, A. K., Kelepouris, E., Kotzker, W. R., Middleton, J. P., Rajpal, M., Roy‐Chaudhury, P., & Chertow, G. M. (2024) · Journal of Primary Care & Community Health · doi:10.1177/21501319241259905 · Cited by 7
Igarashi, A., Tachimori, H., Maruyama‐Sakurai, K., Segawa, Y., Takagi, H., Akiyama, H., Imai, N., Kohsaka, S., & Miyata, H. (2025) · Advances in Therapy · doi:10.1007/s12325-025-03157-z · Cited by 6
Liang, B., Li, R., Zhang, P., & Gu, N. (2022) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-022-10302-4 · Cited by 6
Piccinni, C. P., Dondi, L., Calabria, S., Ronconi, G., Pedrini, A., Lapi, F., Marconi, E., Parretti, D., Medea, G., Cricelli, C. A., et al. (2022) · International Journal of Cardiology · doi:10.1016/j.ijcard.2022.09.053 · Cited by 6
Self-citationSGLT2 Inhibitors and Kidney Diseases: A Clinical Perspective
Theofilis, P., & Kalaitzidis, R. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867330666221227091943 · Cited by 6
Retardo na progressão da doença renal crônica com o uso de inibidores do sglt2: revisão integrativa
Moreira, A. C. L., Basniak, B. B. F., Basniak, L., Berci, M. D. S., & Stival, T. M. (2023) · Research Society and Development · doi:10.33448/rsd-v12i3.40670 · Cited by 6
Matuszewski, W., Tomaszek, L., Szklarz, M., Górny, J. M., Kordas, B., Rutkowska, J., & Juranek, J. K. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14186348 · Cited by 4
Hung, A. M., Beck, C., Greevy, R. A., Hackstadt, A. J., Elasy, T. A., & Roumie, C. L. (2026) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000001033 · Cited by 4
Gliflozins in the Treatment of Non-diabetic Experimental Cardiovascular Diseases
Vaněčková, I., & Zicha, J. (2024) · Physiological Research · doi:10.33549/physiolres.935364 · Cited by 4
Bakis, H., Pfirmann, P., Combe, C., & Rigothier, C. (2022) · Néphrologie & Thérapeutique · doi:10.1016/s1769-7255(22)00649-6 · Cited by 4
Taha, H., Momtaz, M., Elamragy, A. A., Younis, O., & Fahim, M. A. S. (2024) · Heart Failure Reviews · doi:10.1007/s10741-024-10453-3 · Cited by 3
Cau, A., Elliott, M. D., Levin, A., Karunarathna, C., Romann, A., Djurdjev, O., Atiquzzaman, M., & Bevilacqua, M. U. (2025) · Canadian Journal of Kidney Health and Disease · doi:10.1177/20543581251404101 · Cited by 3
Self-citationRossing, P. R., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2025) · Diabetologie und Stoffwechsel · doi:10.1055/a-2481-2004 · Cited by 3
Self-citationDiabetic Kidney Care Redefined with a New Way into Remission
Hammad, N., Hassanein, M., & Rahman, M. U. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2022.08.002 · Cited by 3
SGLT-2 Inhibitors and Renal Outcomes in Non-Diabetic Patients: A Systematic Review
Sousa, M., Almeida, C., Marchão, N., Godinho, I., Lopes, J. A., & Gameiro, J. (2023) · Portuguese Journal of Nephrology & Hypertension · doi:10.32932/pjnh.2023.03.234 · Cited by 3
Zhu, D., Judge, P. K., Francis, S., Che, Z., Rayner, J. J., Buchanan, C. E., Mayne, K. J., Stevens, W., Bley, T. A., Bhandary, N., et al. (2025) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2025.09.022 · Cited by 2
Self-citationClinical value of adding Dapagliflozin in patients with nephrotic syndrome
Elsharkawy, M. M., Emara, A., Ahmed, M. M. M. M., Ghonamy, E., & Teama, N. M. (2024) · International Urology and Nephrology · doi:10.1007/s11255-024-04099-1 · Cited by 2
Abat, S., Abd Rahman, R., Cader, R. A., Abdul Hafidz, M., Abdul Wahab, M., Abdullah, N., Abdulsamad, T., Abe, M., Abraham, N., Acheampong, S., et al. (2023) · UCL Discovery (University College London) · Cited by 2
Self-citationVajgel, G., Säemann, M. D., & Kronbichler, A. (2026) · Glomerular Diseases · doi:10.1159/000551255 · Cited by 1
“Inclusion in the EMPA-KIDNEY trial required an UACR of ≥ 200 mg/g creatinine for those with an eGFR over 45 mL/min/1.73 m 2 but no abnormal albuminuria test was needed for the subset of participants with eGFR ranging from 20 to 45 mL/min/1.73 m 2 [62].”
InfluentialHong, J. H. (2026) · Cardiovascular Prevention and Pharmacotherapy · doi:10.36011/cpp.2026.8.e9 · Cited by 1
“Hard cardiovascular and renal outcomes have been report-ed and are expected to expand the role of SGLT2i in the management of T2DM [28].”
Kardiorenales Syndrom: Herz- und Niereninsuffizienz gleichzeitig im Fokus
Schwenger, V., Latus, J., Mahfoud, F., & Remppis, B. A. (2022) · Deutsches Ärzteblatt · doi:10.3238/perskardio.2022.06.17.01 · Cited by 1
SGLT-2 inhibitors in Lupus Nephropathy. It could be considered an intervention of Nephroprotection
Rico-Fontalvo, J. E., Jiménez, L. C. V., Yánez, T. R., Daza-Arnedo, R., Serpa, O. V. V., Uparella-Gulfo, I., & Álvarez-Estévez, G. (2022) · Revista Paraguaya de Reumatología · doi:10.18004/rpr/2022.08.02.94 · Cited by 1
Cardiorenal effects of SGLT2 inhibitors: who might benefit?
Klug, E., Rayner, B. L., Wasserfall, M., Kok, A., Mpe, M., Ruder, S., Mohamed, N., & Webb, D. (2023) · Journal of Endocrinology Metabolism and Diabetes of South Africa · doi:10.1080/16089677.2023.2275898 · Cited by 1
Kidney and heart: more than two organs
Castelletti, S., & Parati, G. (2022) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwac164 · Cited by 1
Mackenzie, I. S., & MacDonald, T. M. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac415 · Cited by 1
SGLT2-Inhibitoren und Begleiterkrankungen: Schutz für Niere und Herz
Schwenger, V. (2022) · Deutsches Ärzteblatt · doi:10.3238/persdia.2022.07.11.05
Brunori, G. (2022) · The Journal of AMD · doi:10.36171/lamd22.25.3.3
Uso de dapagliflozina en pacientes con nefropatía por IgA: reporte de una serie de cinco casos
Rico-Fontalvo, J. E., Daza-Arnedo, R., Montejo-Hernández, J. D., Romero-Martínez, G., Romero-Martínez, S., & Yánez, T. R. (2022) · Revista Colombiana de Endocrinología Diabetes & Metabolismo · doi:10.53853/encr.9.4.774
What Is the Best Medicine for Chronic Kidney Disease in Diabetes?
Giaccari, A. (2022) · Diabetes Care · doi:10.2337/dci22-0029
Metadata
- Authors
- The EMPA-KIDNEY Collaborative Group, Herrington, W. G., Wanner, C., Green, J. B., Hauske, S. J., Judge, P., Mayne, K. J., Ng, S. Y. A., Sammons, E., Zhu, D., Staplin, N., Preiss, D., Stevens, W., Wallendszus, K., Dayanandan, R., Knott, C., Hill, M., Emberson, J., Brenner, S., Cejka, V., Cheung, A. K., Liu, Z., Li, J., Chen, P., Hooi, L., Liu, W., Kadowaki, T., Nangaku, M., Levin, A., Cherney, D., Pontremoli, R., Maggioni, A. P., Goto, S., Tomita, A., Deo, R., Tuttle, K., Eilbracht, J., Hantel, S., Hopley, M., Landray, M. J., Baigent, C., Haynes, R., Baigent, C., Landray, M. J., Wanner, C., Herrington, W. G., Haynes, R., Green, J. B., Hauske, S. J., Brueckmann, M., Hopley, M., Brenner, S., Cheung, A. K., Preiss, D., Liu, Z., Li, J., Hooi, L., Liu, W., Kadowaki, T., Nangaku, M., Levin, A., Cherney, D., Pontremoli, R., Maggioni, A. P., Staplin, N., Emberson, J., Hantel, S., Goto, S., Deo, R., Tuttle, K., Ng, S. Y. A., Lozano, F. J. R., Sammons, E., Zhu, D., Sandercock, P., Bilous, R., Herzog, C., Whelton, P., Wittes, J., Bennett, D., Burke, A., Brown, R., Dayanandan, R., Fletcher, L., Gosling, H., Harding, E., Haynes, R., Herrington, W. G., Judge, P., Knott, C., Lee, R., Murphy, K., Qiao, Y., Raff, R., Yu, H., Qiao, Y., Cejka, V., Fajardo-Moser, M., Lorimer, A., Lucci, D., Hepditch, A., Axler, A., Chen, P., Hao, D., Goh, C. B., Sivanandam, S., Hashimoto, A., Negoro, W., Tomita, A., & Tomoko, M.
- ORCID
- Venue
- Nephrology Dialysis Transplantation
- Publisher
- Oxford University Press (OUP)
- Published
- 2022-03-03
- Volume
- 37
- Issue
- 7
- Pages
- 1317-1329
- ISSN
- 0931-0509 (ISSN-L)
- 1460-2385
- PMC
- PMC9217655
- OpenAlex
- W4213426937
- Cited by
- 110
- References
- 52
- Citations by year
- 2026: 6 · 2025: 13 · 2024: 23 · 2023: 33 · 2022: 35
- FWCI
- 16.48
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Nephrology Dialysis Transplantation (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Boehringer Ingelheim
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- empagliflozin, SGLT2 inhibitors, chronic kidney disease, kidney disease progression, cardiovascular mortality, diabetic nephropathy, glomerular disease, estimated glomerular filtration rate, urinary albumin-creatinine ratio, trial recruitment, trial design, EMPA-KIDNEY trial, diabetes mellitus
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Benzhydryl Compounds, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Double-Blind Method, Female, Glomerular Filtration Rate, Humans, Kidney, Male, Randomized Controlled Trials as Topic, Disease Progression, Renal Insufficiency, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.